Inflammatory bowel disease serologies in ankylosing spondylitis patients: a pilot study |
| |
| Authors: | Matthew L Mundwiler Ling Mei Carol J Landers John D Reveille Stephan Targan Michael H Weisman |
| |
| Affiliation: | (1) Rockford Orthopedic Associates, 324 Roxbury Rd, Rockford, IL 61107, USA;(2) Center for Inflammatory Bowel Disease, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA 90048, USA;(3) Rheumatology, University of Texas Health Sciences Center, 6431 Fannin Rm 5270, Houston, TX 77030, USA |
| |
| Abstract: | Introduction Ankylosing spondylitis (AS) and inflammatory bowel disease (IBD) share similarities and are classified as spondyloarthropathies. In IBD, anti-Saccharomyces cerevisiae antibody (ASCA), anti-I2 (associated with anti-Pseudomonas activity), anti-Escherichia coli outer membrane porin C (anti-OmpC), anti-flagellin (anti-CBir1), and antineutrophil cytoplasmic antibodies (ANCA) possess clinical significance. Because of the overlap between the two conditions, a pilot study was designed to compare the frequency of these antibodies in AS patients compared to normal controls. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
